nct_id: NCT06380751
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-04-24'
study_start_date: '2024-08-01'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Abemaciclib'
  - drug_name: 'Drug: Exemestane'
  - drug_name: 'Drug: Letrozole'
  - drug_name: 'Drug: Anastrozole'
  - drug_name: 'Drug: Saruparib (AZD5305)'
  - drug_name: 'Drug: Camizestrant'
  - drug_name: 'Drug: Fulvestrant'
  - drug_name: 'Drug: Ribociclib'
  - drug_name: 'Drug: Palbociclib'
long_title: A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus
  Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy
  or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2,
  or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/
  ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
last_updated: '2025-10-14'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: AstraZeneca
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 500
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Adult females, pre/peri-menopausal and/or post-menopausal, and adult males'
- '* Histologically or cytologically documented diagnosis of HR-positive, HER2-negative
  breast cancer'
- '* Advanced breast cancer with either locally advanced disease not amenable to curative
  treatment or metastatic disease'
- '* ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks'
- '* FFPE tumour tissue from each participant'
- '* Documented germline tumour loss of function mutation in BRCA1, BRCA2, or PALB2'
- '* Adequate organ and marrow function'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Participants with history of MDS/AML or with features suggestive of
  MDS/AML
- Exclude - * Participants with any known predisposition to bleeding
- Exclude - * Any history of persisting severe cytopenia
- Exclude - * Any evidence of severe or uncontrolled systemic diseases or active uncontrolled
  infections
- Exclude - * Refractory nausea and vomiting, chronic GI disease, inability to swallow
  the formulated product, or previous significant bowel resection
- Exclude - * History of another primary malignancy
- "Exclude - * Persistent toxicities (CTCAE Grade \u2265 2) caused by previous anti-cancer\
  \ therapy excluding alopecia"
- Exclude - * Spinal cord compression, brain metastases, carcinomatous meningitis,
  or leptomeningeal disease
- Exclude - * Evidence of active and uncontrolled hepatitis B and/or hepatitis C
- Exclude - * Evidence of active and uncontrolled HIV infection
- Exclude - * Active tuberculosis infection
- Exclude - * Cardiac criteria, including history of arrythmia and cardiovascular
  disease
- Exclude - * Concurrent exogenous reproductive hormone therapy or non-topical hormonal
  therapy for non-cancer-related conditions
- Exclude - * Major surgical procedure or significant traumatic injury within 4 weeks
  of the first dose of study intervention or an anticipated need for major surgery
  during the study
- Exclude - * Palliative radiotherapy with a limited field of radiation within 2 weeks
  or with wide field of radiation or to more than 30% of the bone marrow within 4
  weeks before the first dose of study treatment
- Exclude - * Prior treatment with systemic anti-cancer therapy for locoregionally
  recurrent or metastatic disease is not permitted, apart from treatment with ET up
  to 28 days before randomisation
- Exclude - * Prior treatment within 28 days with blood product support or growth
  factor support
- Exclude - * Any systemic concurrent anti-cancer treatment
- 'Exclude - * Concomitant use of the following types of medications or herbal supplements
  within 21 days or at least 5 half-lives of randomisation:'
- Exclude - 1. Strong and moderate CYP3A4 inducers/inhibitors
- Exclude - 2. Sensitive CYP2B6 substrates
- Exclude - 3. Substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic
  index, eg, warfarin (and other coumarin-derived vitamin K antagonist anticoagulants)
  and phenytoin.
- Exclude - * Concomitant use of drugs that are known to prolong QT and have a known
  risk of TdP
- Exclude - * Systemic use of atropine
- 'Exclude - * The following exclusion criteria apply to treatments administered for
  early breast cancer:'
- "Exclude - 1. Disease progression \u2264 84 days following the last dose of neo-adjuvant\
  \ or adjuvant chemotherapy"
- "Exclude - 2. Disease progression \u2264 1 year (365 days) from the last dose of\
  \ treatment with a PARPi and/or platinum agent for early breast cancer"
- "Exclude - 3. Disease progression \u2264 1 year (365 days) from the last dose with\
  \ a CDK4/6i in the adjuvant setting"
- "Exclude - 4. Disease progression \u2264 1 year (365 days) from the last dose of\
  \ an oral SERD including camizestrant."
short_title: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor
  Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0,
  1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: AstraZeneca
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The primary objective of the study is to measure efficacy of saruparib (AZD5305)
  plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with
  BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH
  non-amplified) advanced breast cancer
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Arm 1: saruparib (AZD5305) plus camizestrant'
      arm_internal_id: 0
      arm_description: participants will receive saruparib (AZD5305) orally and camizestrant
        orally
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Saruparib (AZD5305)'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Camizestrant'
        level_internal_id: 1
        level_suspended: N
    - arm_code: 'Arm 2: Physician''s choice CDK4/6i plus physician''s choice ET'
      arm_internal_id: 1
      arm_description: "agents are indicated below and should follow local guidelines:\n\
        \n* Physician's Choice CDK4/6i:\n\n  * abemaciclib orally, or\n  * ribociclib\
        \ orally, or\n  * palbociclib orally.\n* Physician's Choice ET:\n\n  * fulvestrant\
        \ intramuscularly, or\n  * One of the following AIs:\n\n    * letrozole orally,\
        \ or\n    * anastrozole orally, or\n    * exemestane orally"
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Abemaciclib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Ribociclib'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Palbociclib'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Fulvestrant'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Letrozole'
        level_internal_id: 4
        level_suspended: N
      - level_code: '5'
        level_description: 'Drug: Anastrozole'
        level_internal_id: 5
        level_suspended: N
      - level_code: '6'
        level_description: 'Drug: Exemestane'
        level_internal_id: 6
        level_suspended: N
    - arm_code: 'Arm 3: Physician''s choice CDK4/6i plus camizestrant'
      arm_internal_id: 2
      arm_description: participants will receive camizestrant orally. Agents for CDK4/6i
        treatment are indicated above and should follow local guidelines
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Camizestrant'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Abemaciclib'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Ribociclib'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Palbociclib'
        level_internal_id: 3
        level_suspended: N
    match:
    - and:
      - and:
        - or:
          - clinical:
              oncotree_primary_diagnosis: Inflammatory Breast Cancer
          - clinical:
              oncotree_primary_diagnosis: Invasive Breast Carcinoma
        - clinical:
            age_numerical: '>=18'
            her2_status: Negative
            er_status: Positive
            pr_status: Positive
            disease_status:
            - Advanced
            - Locally Advanced
            - Metastatic
            - Early Stage
      - or:
        - genomic:
            hugo_symbol: BRCA1
            variant_category: Mutation
        - genomic:
            hugo_symbol: BRCA2
            variant_category: Mutation
        - genomic:
            hugo_symbol: PALB2
            variant_category: Mutation
